Por favor, use este identificador para citar o enlazar este ítem: 10.14670/HH-11-584

Título: Mutation stability in primary and metastatic melanoma: what we know and what we don’t
Fecha de publicación: 2015
Editorial: F. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de Biología Celular e Histología
Cita bibliográfica: Histology and Histopathology, vol.30, nº 7, (2015)
ISSN: 1699-5848
Materias relacionadas: CDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncología
Palabras clave: Melanoma
Resumen: Despite the efficacy and success of targeted therapies, a significant number of patients with melanoma exhibit either intrinsic or acquired resistance to these drugs. Numerous mechanisms for the development of resistance have been postulated, but the precise reason for this is not known. In this review, we examine the incidence of mutations in select genes (BRAF, NRAS, C-KIT, and GNAQ) known to occur in melanoma, specifically in primary tumors and their paired metastases, to understand the significance of intratumoral heterogeneity by assessing how changes in mutation status alters the process of metastatic spread. Our data revealed a small yet consistent degree of discordance of mutations in the MAPK pathway commonly occurring in melanoma indicating that failed targeted therapy may be a consequence of this.
Autor/es principal/es: Varada, Sowmya
Mahalingam, Meera
URI: http://hdl.handle.net/10201/96222
DOI: 10.14670/HH-11-584
Tipo de documento: info:eu-repo/semantics/article
Número páginas / Extensión: 8
Derechos: info:eu-repo/semantics/openAccess
Attribution-NonCommercial-NoDerivatives 4.0 International
Aparece en las colecciones:Vol.30, nº7 (2015)

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
Varada-30-763-770-2015.pdf133,18 kBAdobe PDFVista previa

Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons